Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

Find the latest Viking Therapeutics, Inc. (VKTX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today...

Jan 29, 2025 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.

Feb 27, 2024 · Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo. Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed.

SAN DIEGO, Jan. 8, 2025 / PRNewswire / -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agon...

Feb 5, 2025 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

3 days ago · VKTX | Complete Viking Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Feb 6, 2025 · Viking Therapeutics, Inc announced its plans for continued development of potential therapies for obesity and other metabolic disorders in a February 5 report of year-end 2024 financials and other corporate news. Of the scientific results provided, Viking CEO Brian Lian, PhD, said, "Each of these studies successfully achieved their objectives ...